Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC280 plus gefitinib in EGFR-mutated, c-MET-amplified NSCLC after EGFR inhibitor progression
NL-OMON41765Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capmatinib and gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities and Adverse events. Started Apr 2012; status: active, not recruiting.
02
Drugs
capmatinibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON41765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41765.